| Literature DB >> 25532421 |
Gordon W Moe1, Justin A Ezekowitz2, Eileen O'Meara3, Serge Lepage4, Jonathan G Howlett5, Steve Fremes6, Abdul Al-Hesayen7, George A Heckman8, Howard Abrams9, Anique Ducharme3, Estrellita Estrella-Holder10, Adam Grzeslo11, Karen Harkness12, Sheri L Koshman2, Michael McDonald9, Robert McKelvie12, Miroslaw Rajda13, Vivek Rao9, Elizabeth Swiggum14, Sean Virani15, Shelley Zieroth10, J Malcolm O Arnold16, Tom Ashton17, Michel D'Astous18, Michael Chan19, Sabe De20, Paul Dorian7, Nadia Giannetti21, Haissam Haddad22, Debra L Isaac5, Simon Kouz23, Marie-Hélène Leblanc24, Peter Liu22, Heather J Ross9, Bruce Sussex25, Michel White3.
Abstract
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing. Third, considerations should be given to treat selected patients with heart failure and preserved systolic function with a mineralocorticoid receptor antagonist and to treat patients with heart failure and reduced ejection fraction with an angiotensin receptor/neprilysin inhibitor, when the drug is approved. As with updates in previous years, the topics were chosen in response to stakeholder feedback. The 2014 Update includes recommendations, values and preferences, and practical tips to assist the clinicians and health care workers to best manage patients with heart failure.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25532421 DOI： 10.1016/j.cjca.2014.10.022
Source DB: PubMed Journal: Can J Cardiol ISSN： 0828-282X Impact factor: 5.223